Phase III randomized pilot study comparing interferon alpha-2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix - PubMed (original) (raw)
Clinical Trial
. 2003 Mar-Apr;13(2):164-9.
doi: 10.1046/j.1525-1438.2003.13031.x.
G Aliste, R Torres, A M Ciudad, M Cuevas, J Garrido, S Prado, A Solá, R Castillo, B Cerda, M A Cumsille, M González, C Navarro, J M Reyes
Affiliations
- PMID: 12657118
- DOI: 10.1046/j.1525-1438.2003.13031.x
Clinical Trial
Phase III randomized pilot study comparing interferon alpha-2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix
R Yazigi et al. Int J Gynecol Cancer. 2003 Mar-Apr.
Abstract
This randomized pilot study was designed to determine whether the addition of interferon alpha-2b to standard radiation therapy offered an advantage in loco-regional control and survival over radiation therapy alone in a homogeneous group of patients with stage IIIB carcinoma of the cervix. Thirty-six patients were treated with a combination of interferon alpha-2b plus radiation therapy, and 38 patients were treated with radiation therapy alone. Patients with evidence of ureteral obstruction were excluded from the study. Evaluation of loco-regional response was determined by pelvic examination, cervical cytology, biopsies and CT scans when indicated. Survival time was measured from initiation of treatment to date of death or last follow-up. Patient characteristics were comparable between both study arms. The objective complete response rate was 67% in the combined therapy group and 55% in the radiation alone group (P = 0.454). With a median follow-up of 17 months for all patients and 31 months for live patients, 50% of the combined group survived vs. 39.5% of the radiation alone group (P = 0.424). We conclude that the addition of interferon alpha-2b to standard radiation therapy did not significantly improve loco-regional response or survival, although such a trend was noted. We encourage the design of a larger randomized study with sufficient power to detect meaningful differences to prove whether the tendency observed in the present investigation holds any promise to improve the outcome of these patients.
Similar articles
- Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix.
Chaney AW, Eifel PJ, Logsdon MD, Morris M, Wharton JT. Chaney AW, et al. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):113-8. doi: 10.1016/s0360-3016(99)00167-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10477014 - Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Song M, DiPaola RS, Cracchiolo BM, Gibbon DG, Hellmann M, Nieves-Neira W, Vaidya A, Wagreich AR, Shih WJ, Rodriguez-Rodriguez L. Song M, et al. Int J Gynecol Cancer. 2014 Nov;24(9):1636-41. doi: 10.1097/IGC.0000000000000258. Int J Gynecol Cancer. 2014. PMID: 25304678 Free PMC article. Clinical Trial. - Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix.
Roberts KB, Urdaneta N, Vera R, Vera A, Gutierrez E, Aguilar Y, Ott S, Medina I, Sempere P, Rockwell S, Sartorelli AC, Fischer DB, Fischer JJ. Roberts KB, et al. Int J Cancer. 2000 Aug 20;90(4):206-23. doi: 10.1002/1097-0215(20000820)90:4<206::aid-ijc4>3.0.co;2-o. Int J Cancer. 2000. PMID: 10993961 Clinical Trial. - Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
Kim JS, Kim JS, Kim SY, Kim Ki, Cho MJ. Kim JS, et al. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. doi: 10.1016/s0360-3016(02)04401-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654434 Review. - [Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)].
Chauvergne J, Rohart J, Héron JF, Aymé Y, Berlié J, Fargeot P, George M, Lebrun-Jezekova D, Pigneux J, Chenal C, et al. Chauvergne J, et al. Bull Cancer. 1990;77(10):1007-24. Bull Cancer. 1990. PMID: 2249011 Review. French.
Cited by
- Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D. Dueñas-González A, et al. Drugs. 2010 Mar 5;70(4):403-32. doi: 10.2165/11534370-000000000-00000. Drugs. 2010. PMID: 20205484 Review. - Radiosensitizers in cervical cancer. Cisplatin and beyond.
Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Candelaria M, et al. Radiat Oncol. 2006 May 8;1:15. doi: 10.1186/1748-717X-1-15. Radiat Oncol. 2006. PMID: 16722549 Free PMC article.